Barclays analyst Luke Sergott raised the firm’s price target on 10x Genomics (TXG) to $17 from $15 and keeps an Overweight rating on the shares. The firm says the company’s new product launches across single cell and spatial put the portfolio in a better spot for when demand does come back.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TXG:
- 10x Genomics: Hold Rating Amid Resilience and Challenges in U.S. Academic and Government Sectors
- 10x Genomics Reports Q3 2025 Financial Results
- 10x Genomics reports Q3 EPS (22c) vs. (30c) last year
- 10x Genomics sees Q4 revenue $154M-$158M, consensus $151.05M
- Cathie Wood Pours into Veracyte Stake ahead of Earnings Beat, Slashes Biotech Holdings